Global biotech company atai Life Sciences, which is developing psychedelic compounds for mental health, today announced the appointment of a new Chief Medical Officer (CMO) and Chief Financial Officer (CFO) in preparation for an upcoming Initial Public Offering (IPO). Greg Weaver and Rolando Gutierrez-Esteinou have joined atai as CFO and CMO, respectively. Greg Weaver, who…